Health TrialsbyHealthPanel

Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

ConditionPlacenta Previa
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGuangzhou Institute of Respiratory Disease

About this trial

This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

Disqualifiers

Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Trial population

This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Causal relationship between plasma VEGFA levels and the risk of placenta previa

This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Time frame
Data analysis and outcome assessment will be completed by December 2024

Secondary outcomes

1

Causal relationship between plasma VEGFB levels and the risk of placenta previa

This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Time frame
Data analysis and outcome assessment will be completed by December 2024
2

Causal relationship between plasma VEGFC levels and the risk of placenta previa

This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Time frame
Data analysis and outcome assessment will be completed by December 2024
3

Causal relationship between plasma PLGF levels and the risk of placenta previa

This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Time frame
Data analysis and outcome assessment will be completed by December 2024

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Guangzhou Institute of Respiratory Disease

Lead sponsor

The Second People's Hospital of Foshan

Collaborator

First People's Hospital of Foshan

Collaborator

Maternal and Child Health Hospital of Foshan

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: